TherapeuticsMD (TXMD) Change in Receivables (2010 - 2022)

TherapeuticsMD's Change in Receivables history runs 13 years deep, the most recent figure standing at -$13.6 million for Q3 2022.

• Quarterly Change in Receivables fell 439.82% year-over-year to -$13.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was -$4.3 million (down 130.19% YoY) and the FY2021 annual result came in at $4.3 million, down 47.39% from the prior year.
• Change in Receivables was -$13.6 million for Q3 2022 at TherapeuticsMD, down from $11.1 million in the prior quarter.
• Across five years, Change in Receivables topped out at $11.1 million in Q2 2022 and bottomed at -$13.6 million in Q3 2022.
• A 5-year average of $1.6 million and a median of $790885.0 in 2018 frame the typical range for Change in Receivables.
• Annual changes were most pronounced in 2018 — Change in Receivables tumbled 2767.32% — and 2022, when it soared 48326.09%.
• TherapeuticsMD's Change in Receivables stood at -$1.8 million in 2018, then soared by 629.91% to $9.3 million in 2019, then slipped by 7.4% to $8.6 million in 2020, then plunged by 114.32% to -$1.2 million in 2021, then sank by 1006.81% to -$13.6 million in 2022.
• Business Quant data shows TXMD's Change in Receivables at -$13.6 million in Q3 2022, $11.1 million in Q2 2022, and -$489000.0 in Q1 2022.